These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 8453691)

  • 41. Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days.
    Stevenson JP; Sun W; Gallagher M; Johnson R; Vaughn D; Schuchter L; Algazy K; Hahn S; Enas N; Ellis D; Thornton D; O'Dwyer PJ
    Clin Cancer Res; 2002 Aug; 8(8):2524-9. PubMed ID: 12171879
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue.
    Lee CK; Rowinsky EK; Li J; Giles F; Moore MJ; Hidalgo M; Capparelli E; Jolivet J; Baker SD
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2158-65. PubMed ID: 16609029
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patients.
    Perez-Ruixo JJ; Zannikos P; Hirankarn S; Stuyckens K; Ludwig EA; Soto-Matos A; Lopez-Lazaro L; Owen JS
    Clin Pharmacokinet; 2007; 46(10):867-84. PubMed ID: 17854236
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study.
    Hochster H; Liebes L; Speyer J; Sorich J; Taubes B; Oratz R; Wernz J; Chachoua A; Blum RH; Zeleniuch-Jacquotte A
    Clin Cancer Res; 1997 Aug; 3(8):1245-52. PubMed ID: 9815806
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma.
    Falcone A; Antonuzzo A; Danesi R; Allegrini G; Monica L; Pfanner E; Masi G; Ricci S; Del Tacca M; Conte P
    Cancer; 1999 Aug; 86(3):470-6. PubMed ID: 10430255
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fixed higher dose schedule of suramin plus hydrocortisone in patients with hormone refractory prostate carcinoma a multicenter Phase II study.
    Calvo E; Cortés J; Rodríguez J; Sureda M; Beltrán C; Rebollo J; Martínez-Monge R; Berián JM; de Irala J; Brugarolas A
    Cancer; 2001 Nov; 92(9):2435-43. PubMed ID: 11745301
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors.
    Rowinsky EK; Noe DA; Trump DL; Winer EP; Lucas VS; Wargin WA; Hohneker JA; Lubejko B; Sartorius SE; Ettinger DS
    J Clin Oncol; 1994 Sep; 12(9):1754-63. PubMed ID: 8083697
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin.
    Bitton RJ; Figg WD; Venzon DJ; Dalakas MC; Bowden C; Headlee D; Reed E; Myers CE; Cooper MR
    J Clin Oncol; 1995 Sep; 13(9):2223-9. PubMed ID: 7666080
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adaptive control with feedback of suramin using intermittent infusions.
    Figg WD; Stevens JA; Cooper MR
    J Clin Oncol; 1994 Jul; 12(7):1523-4. PubMed ID: 8021743
    [No Abstract]   [Full Text] [Related]  

  • 50. Pharmacokinetics of cis-diamminedichloroplatinum (II) given as low-dose and high-dose infusions.
    Kurihara N; Kubota T; Hoshiya Y; Otani Y; Ando N; Kumai K; Kitajima M
    J Surg Oncol; 1996 Jun; 62(2):135-8. PubMed ID: 8649040
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors.
    Tranchand B; Catimel G; Lucas C; Sarkany M; Bastian G; Evene E; Guastalla JP; Négrier S; Rebattu P; Dumortier A; Foy M; Grossin F; Mazier B; Froudarakis M; Barbet N; Clavel M; Ardiet C
    Cancer Chemother Pharmacol; 1998; 41(4):281-91. PubMed ID: 9488597
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Uptake of suramin by human microvascular endothelial cells.
    Gagliardi AR; Taylor MF; Collins DC
    Cancer Lett; 1998 Mar; 125(1-2):97-102. PubMed ID: 9566702
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors.
    Herben VM; van Gijn R; Schellens JH; Schot M; Lieverst J; Hillebrand MJ; Schoemaker NE; Porro MG; Beijnen JH; ten Bokkel Huinink WW
    J Clin Oncol; 1999 Jun; 17(6):1906-14. PubMed ID: 10561232
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetics of taurolidine following repeated intravenous infusions measured by HPLC-ESI-MS/MS of the derivatives taurultame and taurinamide in glioblastoma patients.
    Stendel R; Scheurer L; Schlatterer K; Stalder U; Pfirrmann RW; Fiss I; Möhler H; Bigler L
    Clin Pharmacokinet; 2007; 46(6):513-24. PubMed ID: 17518510
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480.
    Small EJ; Halabi S; Ratain MJ; Rosner G; Stadler W; Palchak D; Marshall E; Rago R; Hars V; Wilding G; Petrylak D; Vogelzang NJ
    J Clin Oncol; 2002 Aug; 20(16):3369-75. PubMed ID: 12177096
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Use of adaptive control with feedback to individualize suramin dosing.
    Scher HI; Jodrell DI; Iversen JM; Curley T; Tong W; Egorin MJ; Forrest A
    Cancer Res; 1992 Jan; 52(1):64-70. PubMed ID: 1727387
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer.
    Thompson P; Balis F; Serabe BM; Berg S; Adamson P; Klenke R; Aiken A; Packer R; Murry DJ; Jakacki R; Blaney SM
    Cancer Chemother Pharmacol; 2003 Nov; 52(5):417-23. PubMed ID: 12879279
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer.
    Kelly WK; Curley T; Leibretz C; Dnistrian A; Schwartz M; Scher HI
    J Clin Oncol; 1995 Sep; 13(9):2208-13. PubMed ID: 7545218
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM).
    Zannikos PN; Rohatagi S; Jensen BK; DePhillips SL; Rhodes GR
    J Clin Pharmacol; 2000 Oct; 40(10):1129-40. PubMed ID: 11028252
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies.
    Ryan DP; Supko JG; Eder JP; Seiden MV; Demetri G; Lynch TJ; Fischman AJ; Davis J; Jimeno J; Clark JW
    Clin Cancer Res; 2001 Feb; 7(2):231-42. PubMed ID: 11234874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.